Morgan Stanley Reiterates Equal-Weight on ADC Therapeutics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Equal-Weight rating on ADC Therapeutics (NYSE:ADCT) and lowered the price target from $5 to $2.
July 11, 2023 | 3:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on ADC Therapeutics and lowered the price target from $5 to $2.
The lowering of the price target by Morgan Stanley from $5 to $2 indicates a bearish outlook for ADC Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100